248
Participants
Start Date
May 25, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
zamtocabtagene autoleucel (MB-CART2019.1)
Chimeric antigen receptor (CAR) T cell therapy
Cyclophosphamide
Lymphodepleting chemotherapy
Fludarabine
Lymphodepleting chemotherapy
Bendamustine
Lymphodepleting chemotherapy
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Allegheny Health Network Cancer Institute, Pittsburgh
WITHDRAWN
University of Pittsburgh - Hillman Cancer Center, Pittsburgh
RECRUITING
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RECRUITING
Duke University Medical Center - Division of Hematologic Malignancies, Durham
RECRUITING
Winship Cancer Institute of Emory University, Atlanta
RECRUITING
Georgia Cancer Center at Augusta University, Augusta
RECRUITING
Baptist Health Miami Cancer Institute, Miami
RECRUITING
The Ohio State University Wexner Medical Center James Cancer, Columbus
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Robert H Lurie Cancer Center, Chicago
RECRUITING
University of Kansas Cancer Center, Westwood
TERMINATED
University of Nebraska Medical Center, Omaha
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
Mayo Clinic, Phoenix
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
UC San Diego Health, La Jolla
RECRUITING
Stanford University, Stanford
RECRUITING
Oregon Health and Science University Knight Cancer Institute, Portland
RECRUITING
Yale University, New Haven
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
University of Alberta Cross Cancer Institute, Edmonton
RECRUITING
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Miltenyi Biomedicine GmbH
INDUSTRY